Immutep Limited (FRA:YP1B)

Market Cap	213.12M
Revenue (ttm)	2.92M
Net Income (ttm)	-26.22M
Shares Out	n/a
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	91
Open	0.1280
Previous Close	0.1210
Day's Range	0.1280 - 0.1280
52-Week Range	0.1080 - 0.2300
Beta	n/a
RSI	55.69
Earnings Date	Jul 29, 2025

About Immutep

Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 31
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: YP1B

Financial Performance

In 2024, Immutep's revenue was 3.84 million, an increase of 9.59% compared to the previous year's 3.51 million. Losses were -42.72 million, 7.07% more than in 2023.

Financial numbers in AUD